Saint john's wort, an herbal inducer of the cytochrome P4503A4 isoform, may alleviate symptoms of willis-ekbom's disease

Clinics

Volumn 68, Issue 4, 2013, Pages 469-474

  Pereira, Jose Carlos ^a   Pradella Hallinan, Marcia ^b   Alves, Rosana Cardoso ^c  

^a Departamento de Psicobiologia ^*

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

CYP4503A4; Restless legs syndrome; Restless legs syndrome treatment; Saint john's wort; Thyroid hormone; Willis ekbom's disease

Indexed keywords

EID: 84878147127     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2013(04)06     Document Type: Article

References (41)

1. Ekbom K-A. Restless legs: a clinical study. Acta Med Scand. 1945;158: 1-122.
2. Ekbom Jr. K, J Ulfberg. Restless Legs Syndrome. J Intern Med. 2009; 266(5):419-31, http://dx.doi.org/10.1111/j.1365-2796.2009.02159.x.
3. Allen R. Restless Legs Syndrome (Willis-Ekbom's Disease); in Carney PR, Geyer JD, and Berry RB: Clinical Sleep Disorders, 2nd edition, 2012, Lippincott Williams & Wilkins. Philadelphia. Pgs 203-18.
4. Eckeli AL, Gitái LL, Dach F, Ceretta H, Sander HH, Passos AD, et al. Prevalence of restless legs syndrome in the rural town of Cassia dos Coqueiros in Brazil. Sleep Med. 2011;12(8):762-7, http://dx.doi.org/10. 1016/j.sleep.2011.01.018.
5. Pereira Jr JC, Pradella-Hallinan M, and Lins Pessoa JH. Imbalance between thyroid hormones and the dopaminergic system might be central to restless legs syndrome pathophysiology: A hypothesis. Clinics. 2010;65(5):547-54, http://dx.doi.org/10.1590/S1807-59322010000500013.
6. Delitala G. Dopamine and T.S.H secretion in man. Lancet. 1977;310:760-1, http://dx.doi.org/10.1016/S0140-6736(77)90259-8.
7. Visser TJ. Pathways of thyroid hormone metabolism. Acta Med. Austriaca. 1996;23:10-6.
8. Bruntom L, Parker K, Blumenthal D, and Buxton I. Goodman & Gilman's Manual of Pharmacology and Therapeutics. McGraw-Hill, New York, 2008.
9. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, et al. SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010;38(Database issue):D237-43, http://dx.doi.org/10.1093/nar/gkp970.
10. Wójcikowski J, Daniel WA. The brain dopaminergic system as an important center regulating liver cytochrome P450 in the rat. Expert Opin Drug Metab Toxicol. 2009;5(6):631-45, http://dx.doi.org/10.1517/ 17425250902973703.
11. Wójcikowski J, Golembiowska K, Daniel WA. Regulation of liver cytochrome P450 by activation of brain dopaminergic system: Physiological and pharmacological implications. Biochem Pharmacol. 2008;(12)675-9.
12. Shupnik MA, Greenspan SL, and Ridgway EC. Transcriptional regulation of thyrotropin subunit by thyrotropin-releasing hormone and dopamine in pituitary cell culture. J. Biol. Chem. 1986;261(12): 675-9.
13. Thummel KE, Wilkinson GR. In Vivo and in Vitro Drug Interactions involving Human CYP3A. Ann Rev Pharmacol Toxicol. 1998;38:389-430, http://dx.doi.org/10.1146/annurev.pharmtox.38.1.389.
14. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). http://medicine. iupui.edu/clinpharm/ddis/table.aspx. Accessed: June, 30, 2012.
15. Antonini A, Calandrella D. Pharmacokinetic evaluation of pramipexole. Expert Opin Drug MetabToxicol. 2011;7(10):1307-14, http://dx.doi.org/ 10.1517/17425255.2011.614232.
16. Schilling JC, Adamus WS, and Palluk R. Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans. Clin Pharmacol Ther. 1992;51(5):541-8, http://dx.doi.org/10.1038/clpt. 1992.60.
17. Hening WA, Allen RP, Walters AS, and Chokroverty S. Motor Functions and Dysfunctions of Sleep; in Chokroverty S, editor. Sleep Disorders Medicine, 2009; Saunders, Elsevier. Philadelphia. Pgs 397-435.
18. Guyton AC, Hall JE. Textbook of Medical Physiology, 11th edition. Elsevier Ltd, 2006.
19. Lys CV, Verstreken P. Mitochondria at the synapse. Neuroscientist. 2006;12(4):291-9.
20. Goglia F, Moreno M, Lanni A. Action of thyroid hormones at the cellular level: the mitochondrial target. FEBS Lett. 1999;452(3):115-20, http://dx. doi.org/10.1016/S0014-5793(99)00642-0.
21. Nunez J, Celi FS, Ng L, Forrest D. Multigenic control of thyroid functions in the nervous system. Mol Cell Endocrinol. 2008;287(1-2):1-12, http:// dx.doi.org/10.1016/j.mce.2008.03.006.
22. Burnstock G, Krugel U, Abbrachio MP, Illes P. Purinergic signaling: from normal behaviour to pathological brain function. Prog Neurobiol. 2011;95(2):229-74, http://dx.doi.org/10.1016/j.pneurobio.2011.08.006.
23. Ropper AH, Samuels MA. Adams and Victor's Principles of Neurology, 9th edition, 2009. McGraw Hill. New York.
24. Lavie P. Sleep-Wake as a biological rhythm. Annu Rev Psychol. 2001;52:277-303, http://dx.doi.org/10.1146/annurev.psych.52.1.277.
25. Pereira Jr. JC, Alves RC. The "forbidden zone for sleep" might be caused by the evening thyrotropin surge and its biological purpose is to enhance survival: a hypothesis. Sleep Sci. 2011;4(3):105-9.
26. Brabant G, Prank K, Ranft U, Schuermeyer TOF, Wagner H, Hauser B, et al. Physiological regulation of circadian and pulsatile thyrotropin secretion in normal man and woman. J Clin Endocrinol Metab. 1990;70(2):403-9, http://dx.doi.org/10.1210/jcem-70-2-403.
27. Trenkwalder C, Hening WA, Montagna P, Oertel WH, Allen RP, Walters AS, Costa J, Stiasny-Kolster K, and Sampaio C. Treatment of restless legs syndrome: An evidence-based review and implications for clinical practice. Mov Disord. 2008;23(16):2267-302, http://dx.doi.org/10.1002/ mds.22254.
28. Lindvall O, Bjorklund A, and Scargerberg G. Dopamine-containing neurons in the spinal cord: Anatomy and some functional aspects. Ann Neurol. 1983;14(3):255-60, http://dx.doi.org/10.1002/ana.410140302.
29. Clemens S, Rye D, and Hochman S. Restless legs syndrome. Revisiting the dopamine hypothesis from the spinal cord perspective. NEUROLOGY, 2006;67:125-30, http://dx.doi.org/10.1212/01.wnl.0000223316.53428.c9.
30. Ekbom KA. Restless Legs in Amputees. Acta Med Scand. 1961;169(4) s419-21.
31. Pereira Jr. JC, Alves Rs C. The principle of labelled-lines of the somatosensory system physiology might explain the phantom limb phenomenon. Med Hypotheses. 2011;77(5):853-6, http://dx.doi.org/10. 1016/j.mehy.2011.07.054.
32. Pereira Jr. JC, Silva Neto JLP, Pradella-Hallinan M. Restless legs syndrome in subjects with knee prosthesis: Evidence that symptoms are generated in the periphery. Clinics. 2011;66(11):1955-9, http://dx.doi. org/10.1590/S1807-59322011001100017.
33. Green ST. Intrathyroidal autonomic nerves can directly influence hormone release from rat thyroid follicles: study in vitro employing electrical field stimulation and intracellular microelectrodes. Clin Sci (Lond). 1987;72(2):233-8.
34. Allen RP, Adler CH, Du W, Butcher A, Bregman DB, Earley CJ. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med. 2011;12(9):906-13, http://dx.doi.org/10.1016/j.sleep.2011.06.009.
35. Connor JR, Ponnuru P, Wang XS, Patton SM, Allen RP, Earley CJ. Profile of altered brain iron acquisition in restless legs syndrome. Brain. 2011;134(Pt 4):959-68, http://dx.doi.org/10.1093/brain/awr012.
36. Rye DB, and Freeman AAH. Dopamine in behavioral state control, in Monti JM, Pandi-Perumal SR, and Sinton CM: Neurochemistry of Sleep and Wakefulness. Cambridge University press. Cambridge 2008. Pgs 179-223.
37. Barnes J, Anderson LA, Phillipson JD. (2001), St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol. 2001;53(5):583-600, http://dx.doi.org/10. 1211/0022357011775910.
38. Moore LB, Goodwin B, Jones SA, Wisely BG, Serebjit-Singh CJ, Willson TM, et al. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. PNAS. 2000;97(13):7500-502, http://dx.doi.org/10.1073/pnas.130155097.
39. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4(2):101-19, http://dx.doi.org/10. 1016/S1389-9457(03)00010-8.
40. Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003;4(2):121-32.
41. Masuko AH, Carvalho LB, Machado MA, Morais JF, Prado LB, Prado GF. Translation and validation into the Brazilian Portuguese of the restless legs syndrome rating scale of the International Restless Legs Syndrome Study Group. Arq Neuropsiquiatr. 2008;66(4):832-6, http:// dx.doi.org/10.1590/S0004-282X2008000600011.